台湾出现携带PBP3插入的产KPC肺炎克雷伯菌
该研究报道了2021年台湾临床分离的产KPC肺炎克雷伯菌ST11序列型菌株携带新型PBP3 YRIT插入,导致对氨曲南/阿维巴坦和头孢他啶/阿维巴坦敏感性降低。功能与遗传学研究表明,PBP3插入损害β-内酰胺结合,与blaKPC-2及其他β-内酰胺酶共同作用降低敏感性。
要点
- 产KPC肺炎克雷伯菌ST11克隆中出现新型PBP3 YRIT插入。
- 该插入与blaKPC-2等β-内酰胺酶共同导致氨曲南/阿维巴坦和头孢他啶/阿维巴坦敏感性降低。
- 提示需加强基因组监测以识别此类耐药机制。
核心结论
- 产KPC肺炎克雷伯菌ST11克隆中出现了新型PBP3 YRIT插入,导致对氨曲南/阿维巴坦和头孢他啶/阿维巴坦敏感性降低。
研究设计与样本
- 研究报道临床分离的产KPC肺炎克雷伯菌ST11菌株,并进行功能与遗传学研究。
主要发现
- PBP3 YRIT插入与blaKPC-2及其他β-内酰胺酶共同作用,降低对氨曲南/阿维巴坦和头孢他啶/阿维巴坦的敏感性。
- 功能与遗传学研究表明PBP3插入损害β-内酰胺结合。
临床怎么用
- 对产KPC肺炎克雷伯菌ST11等高危克隆应加强基因组监测,以识别PBP3插入等耐药机制。
- 面对氨曲南/阿维巴坦敏感性降低的CRE感染,需考虑PBP3插入可能并审慎选择治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Carbapenem-resistant Enterobacterales (CRE) are a major global health threat with limited treatment options. Aztreonam/avibactam is a promising therapy against metallo-β-lactamase (MBL)-producing and other CRE, but emerging resistance threatens its effectiveness. Insertions in penicillin-binding protein 3 (PBP3), which are well described in Escherichia coli, are linked to reduced aztreonam/avibactam susceptibility but remain poorly characterized in Klebsiella pneumoniae. We report clinical K. pneumoniae carbapenemase-producing K. pneumoniae sequence type 11 isolates carrying a novel PBP3 YRIT insertion, conferring reduced susceptibility to aztreonam/avibactam and ceftazidime/avibactam. Functional and genetic studies suggest that the PBP3 insertion impairs β-lactam binding and, in combination with blaKPC-2 and other β-lactamases, contributes to reduced susceptibility. Those findings demonstrate the emergence of a PBP3 insertion in a high-risk K. pneumoniae clone, underscoring the expansion of this resistance mechanism and the critical need for genomic surveillance and novel therapeutics to identify and treat such infections.
引用
- Long T, Lovey A, Sanborn L, et al. Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021. Emerg Infect Dis. 2026. PMID: 42103067. doi:10.3201/eid3206.260478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。